CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

VI-0810 is under development for the treatment of diabetes. Vivus, a subsidiary of Icahn Enterprises LP, is developing drugs for the treatment of exocrine pancreatic insufficiency, obesity and ...

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor.